Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.52 |
| ▸ | TDO2 | P48775 | 4/20 | 0.52 |
| ▸ | AVPR1A | P37288 | 9/20 | 0.46 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138037 | 0.91 | IDO1 (0.60) | IDO1TDO2AVPR1AOXTRRAB9A | |
| SCHEMBL22648473 | 0.89 | FASN (0.52) | IDO1TDO2 | |
| SCHEMBL22648520 | 0.89 | IDO1 (0.65) | IDO1TDO2RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21138032 | 0.85 | IDO1 (0.56) | IDO1TDO2AVPR1AOXTRNPC1 | |
| SCHEMBL22648363 | 0.83 | IDO1 (0.51) | IDO1TDO2AVPR1AOXTRSMN1; SMN2 | |
| SCHEMBL2158862 | 0.81 | AVPR1A (0.52) | AVPR1AOXTR | |
| SCHEMBL22648354 | 0.80 | IDO1 (0.60) | IDO1TDO2AVPR1AOXTRALDH1A1 | |
| SCHEMBL21138071 | 0.78 | IDO1 (0.56) | IDO1TDO2AVPR1AOXTRNPC1 | |
| SCHEMBL22648347 | 0.76 | IDO1 (0.67) | IDO1TDO2AVPR1AOXTRALDH1A1 | |
| SCHEMBL22648448 | 0.76 | AVPR1A (0.39) | IDO1TDO2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| WO-2019115586-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | IDO1 1/4885TDO2 7/4885AVPR1A 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.